JP2012158602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012158602A5 JP2012158602A5 JP2012104769A JP2012104769A JP2012158602A5 JP 2012158602 A5 JP2012158602 A5 JP 2012158602A5 JP 2012104769 A JP2012104769 A JP 2012104769A JP 2012104769 A JP2012104769 A JP 2012104769A JP 2012158602 A5 JP2012158602 A5 JP 2012158602A5
- Authority
- JP
- Japan
- Prior art keywords
- mol
- cholesterol
- sphingomyelin
- liposome
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 42
- 235000012000 cholesterol Nutrition 0.000 claims 21
- 229960004528 vincristine Drugs 0.000 claims 21
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 21
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 239000002502 liposome Substances 0.000 claims 11
- 239000000243 solution Substances 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 239000007979 citrate buffer Substances 0.000 claims 4
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical group OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 claims 4
- 229960002110 vincristine sulfate Drugs 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 238000001802 infusion Methods 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000008363 phosphate buffer Substances 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 231100000189 neurotoxic Toxicity 0.000 claims 1
- 230000002887 neurotoxic effect Effects 0.000 claims 1
- 239000008055 phosphate buffer solution Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12744499P | 1999-04-01 | 1999-04-01 | |
| US60/127,444 | 1999-04-01 | ||
| US13719499P | 1999-06-02 | 1999-06-02 | |
| US60/137,194 | 1999-06-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000609037A Division JP2002541088A (ja) | 1999-04-01 | 2000-03-31 | リンパ腫の治療のための組成物および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014246221A Division JP2015071631A (ja) | 1999-04-01 | 2014-12-04 | リンパ腫の治療のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012158602A JP2012158602A (ja) | 2012-08-23 |
| JP2012158602A5 true JP2012158602A5 (enExample) | 2013-05-30 |
| JP5981214B2 JP5981214B2 (ja) | 2016-08-31 |
Family
ID=26825635
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000609037A Pending JP2002541088A (ja) | 1999-04-01 | 2000-03-31 | リンパ腫の治療のための組成物および方法 |
| JP2012104769A Expired - Lifetime JP5981214B2 (ja) | 1999-04-01 | 2012-05-01 | リンパ腫の治療のための組成物および方法 |
| JP2014246221A Pending JP2015071631A (ja) | 1999-04-01 | 2014-12-04 | リンパ腫の治療のための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000609037A Pending JP2002541088A (ja) | 1999-04-01 | 2000-03-31 | リンパ腫の治療のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014246221A Pending JP2015071631A (ja) | 1999-04-01 | 2014-12-04 | リンパ腫の治療のための組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| EP (3) | EP1169021B1 (enExample) |
| JP (3) | JP2002541088A (enExample) |
| AT (1) | ATE442839T1 (enExample) |
| AU (1) | AU777572B2 (enExample) |
| BR (1) | BRPI0009448B8 (enExample) |
| CA (1) | CA2366787C (enExample) |
| CY (1) | CY1109641T1 (enExample) |
| DE (1) | DE60042968D1 (enExample) |
| DK (2) | DK1169021T3 (enExample) |
| ES (2) | ES2524141T3 (enExample) |
| IL (4) | IL145720A0 (enExample) |
| PT (1) | PT1169021E (enExample) |
| WO (1) | WO2000059473A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6723338B1 (en) | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
| EP1169021B1 (en) * | 1999-04-01 | 2009-09-16 | Hana Biosciences, Inc. | Compositions and methods for treating lymphoma |
| US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| HK1049787B (en) | 1999-10-01 | 2014-07-25 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| JP2004524368A (ja) * | 2001-03-27 | 2004-08-12 | フェアーズ ファーマシューティカル リサーチ エヌ．ヴェー． | 低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物 |
| EP2105135B1 (en) * | 2002-05-17 | 2014-10-22 | Celgene Corporation | Pharmaceutical compositions for treating cancer |
| US6890558B2 (en) | 2002-05-31 | 2005-05-10 | R.P. Scherer Technologies, Inc. | Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment |
| FR2840203B1 (fr) * | 2002-05-31 | 2004-08-27 | Scherer Technologies Inc R P | Composition pharmaceutique orale pour capsules molles contenant vinorelbine et methode de traitement |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| RU2252764C2 (ru) * | 2003-03-04 | 2005-05-27 | Российский научный центр рентгенорадиологии МЗ РФ | Способ комплексного лечения лимфогранулематоза |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| WO2005011698A1 (en) * | 2003-07-28 | 2005-02-10 | Inex Pharmaceuticals Corporation | Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia |
| BRPI0513007A (pt) * | 2004-07-09 | 2008-04-22 | Schering Ag | terapia de combinação com anticorpo anti-cd20 marcado radioativamente no tratamento de linfoma de célula b |
| AU2005272946B2 (en) * | 2004-08-10 | 2012-01-12 | Talon Therapeutics, Inc. | Compositions and methods for treating leukemia |
| HRP20160430T1 (hr) | 2007-09-10 | 2016-05-20 | Boston Biomedical, Inc. | Nova grupa inhibitora stat3 puta i inhibitora puta matičnih stanica karcinoma |
| KR102449659B1 (ko) | 2008-03-18 | 2022-09-29 | 제넨테크, 인크. | 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법 |
| CA2741265A1 (en) * | 2008-10-24 | 2010-04-29 | Gloucester Pharmaceuticals | Cancer therapy |
| US9801874B2 (en) * | 2012-11-20 | 2017-10-31 | Spectrum Pharmaceuticals | Method for the preparation of liposome encapsulated vincristine for therapeutic use |
| US20140205543A1 (en) * | 2013-01-24 | 2014-07-24 | Memorial Sloan-Kettering Cancer Center | Method for diagnosing or treating tumors using sphingomyelin containing liposomes |
| KR20150139955A (ko) | 2013-04-09 | 2015-12-14 | 보스톤 바이오메디칼, 인크. | 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온 |
| TWI678213B (zh) * | 2015-07-22 | 2019-12-01 | 美商史倍壯製藥公司 | 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物 |
| US11299469B2 (en) | 2016-11-29 | 2022-04-12 | Sumitomo Dainippon Pharma Oncology, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| US10646464B2 (en) | 2017-05-17 | 2020-05-12 | Boston Biomedical, Inc. | Methods for treating cancer |
| SI26542A (sl) | 2023-09-12 | 2025-03-31 | Univerza V Ljubljani | Nove liposomske formulacije in postopek za njihovo pripravo |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US5736155A (en) | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4885172A (en) | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
| US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
| US5171578A (en) | 1985-06-26 | 1992-12-15 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4952408A (en) * | 1988-05-23 | 1990-08-28 | Georgetown University | Liposome-encapsulated vinca alkaloids and their use in combatting tumors |
| US4957773A (en) | 1989-02-13 | 1990-09-18 | Syracuse University | Deposition of boron-containing films from decaborane |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5165922A (en) * | 1990-05-22 | 1992-11-24 | Bristol-Myers Squibb Company | Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy |
| GB9304745D0 (en) * | 1993-03-09 | 1993-04-28 | Oncholab Ab | Use of pharmaceutical formulations |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5714163A (en) * | 1994-06-27 | 1998-02-03 | Nexstar Pharmaceuticals, Inc. | Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5837282A (en) | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| EP1169021B1 (en) * | 1999-04-01 | 2009-09-16 | Hana Biosciences, Inc. | Compositions and methods for treating lymphoma |
-
2000
- 2000-03-31 EP EP00920004A patent/EP1169021B1/en not_active Expired - Lifetime
- 2000-03-31 DK DK00920004T patent/DK1169021T3/da active
- 2000-03-31 CA CA2366787A patent/CA2366787C/en not_active Expired - Lifetime
- 2000-03-31 ES ES10011105.3T patent/ES2524141T3/es not_active Expired - Lifetime
- 2000-03-31 PT PT00920004T patent/PT1169021E/pt unknown
- 2000-03-31 DK DK10011105.3T patent/DK2266537T3/en active
- 2000-03-31 JP JP2000609037A patent/JP2002541088A/ja active Pending
- 2000-03-31 WO PCT/US2000/008669 patent/WO2000059473A1/en not_active Ceased
- 2000-03-31 DE DE60042968T patent/DE60042968D1/de not_active Expired - Lifetime
- 2000-03-31 BR BRPI0009448A patent/BRPI0009448B8/pt not_active IP Right Cessation
- 2000-03-31 ES ES00920004T patent/ES2333400T3/es not_active Expired - Lifetime
- 2000-03-31 IL IL14572000A patent/IL145720A0/xx unknown
- 2000-03-31 EP EP08003804A patent/EP1985285A3/en not_active Withdrawn
- 2000-03-31 AT AT00920004T patent/ATE442839T1/de active
- 2000-03-31 EP EP10011105.3A patent/EP2266537B1/en not_active Expired - Lifetime
- 2000-03-31 AU AU40606/00A patent/AU777572B2/en not_active Expired
-
2001
- 2001-09-30 IL IL145720A patent/IL145720A/en not_active IP Right Cessation
-
2009
- 2009-11-17 CY CY20091101201T patent/CY1109641T1/el unknown
-
2011
- 2011-04-14 IL IL212389A patent/IL212389A/en not_active IP Right Cessation
- 2011-04-14 IL IL212390A patent/IL212390A/en not_active IP Right Cessation
-
2012
- 2012-05-01 JP JP2012104769A patent/JP5981214B2/ja not_active Expired - Lifetime
-
2014
- 2014-12-04 JP JP2014246221A patent/JP2015071631A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012158602A5 (enExample) | ||
| US11554178B2 (en) | Compositions and methods of modulating macrophage activity | |
| ES2590778T3 (es) | Compuestos de quinolina sustituida | |
| JP7025416B2 (ja) | 好中球減少症を低減させるための組成物および方法 | |
| JP2019501204A5 (enExample) | ||
| JP2012067116A5 (enExample) | ||
| TWI626061B (zh) | 治療癌症之奈米粒子及其用途 | |
| RU2013149282A (ru) | Комбинации и способы введения терапевтических агентов и комбинированная терапия | |
| EP2920187B1 (en) | A method of using binuclear gold(i) compounds for cancer treatment | |
| JP2014510729A5 (enExample) | ||
| JP2015501833A5 (enExample) | ||
| RU2018120318A (ru) | ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| RU2016141322A (ru) | Терапевтическое применение агониста tlr и комбинированная терапия | |
| JP2010514787A5 (enExample) | ||
| JP2010539098A5 (enExample) | ||
| JP2009513662A5 (enExample) | ||
| JO3659B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية | |
| WO2009120697A4 (en) | Method and compositions for treatment of cancer | |
| JP2019521180A5 (enExample) | ||
| WO2012065079A4 (en) | Methods of treating cancer | |
| KR20190025733A (ko) | 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법 및 약학적 조성물 | |
| JP2012522841A5 (enExample) | ||
| JP2010528091A (ja) | ビンフルニンおよびトラスツズマブを含んでなる癌治療の組合せ療法 | |
| Quiñonero et al. | Combining olaparib and ascorbic acid on nanoparticles to enhance the drug toxic effects in pancreatic cancer | |
| JP2013504590A5 (enExample) |